Pfizer's Bet On Oncology

Pfizer's Oncology segment accounts for less than 20% of the company's value, according to our estimates. For many other major pharma companies, their oncology portfolios are larger contributors to their top lines, and Pfizer has been looking to capitalize on opportunities in the space.